SAN DIEGO, CA — November 19, 2025 — Leads & Copy — Quantumzyme Corp. (OTCQB: QTZM) announced its participation in the Catalysis and Chemical Engineering Conference (CCE-2026), scheduled for March 9–11, 2026, in Boston, MA.
At the event, Quantumzyme will showcase how its enzyme engineering platform is transforming chemical synthesis and enabling sustainable, cost-effective methods for pharmaceutical manufacturing.
Quantumzyme’s presence at CCE-2026 highlights its growing role in promoting green chemistry solutions for the biomanufacturing sector, driven by increasing global demand for low-waste, energy-efficient pharmaceutical production.
The company plans to present its latest advancements in green ibuprofen synthesis, including biocatalytic routes designed to lower environmental impact and manufacturing costs. Quantumzyme will also discuss its enzyme engineering platform’s expansion to high-volume Active Pharmaceutical Ingredients (APIs), including new applications in chiral molecule synthesis using next-generation ketoreductase (KRED) enzymes.
These advancements demonstrate Quantumzyme’s ongoing commitment to delivering practical, scalable solutions that support cleaner and more efficient pharmaceutical production.
Quantumzyme’s technology aligns with global sustainability and decarbonization goals, and U.S. initiatives to strengthen domestic API manufacturing capacity. Traditional API production methods often generate significant waste and require high solvent usage.
Quantumzyme’s platform enables greener and more reliable biocatalytic pathways, aiming to:
- Reduce waste and solvent consumption
- Lower carbon intensity in API production
- Improve process reliability and consistency
- Support U.S. onshoring and supply-chain resilience for essential medicines
These capabilities position Quantumzyme to contribute to the broader transformation of pharmaceutical manufacturing toward environmentally responsible production.
Throughout CCE-2026, Quantumzyme intends to engage with researchers, academic collaborators, pharmaceutical manufacturers, process development and engineering teams, technology developers, innovation partners, and investors focused on green chemistry and biomanufacturing, seeking partnerships to accelerate the adoption of enzyme-based manufacturing approaches across high-volume API production.
Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp., said that CCE-2026 provides an excellent platform to share the company’s vision for sustainable chemical manufacturing.
Quantumzyme Corp. is a biotransformation company specializing in green chemistry. It uses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts. These biocatalysts enhance efficiency, reduce waste, and minimize environmental impact.
Quantumzyme offers end-to-end enzyme development services, including discovery, engineering, process optimization, and scale-up, empowering its partners to adopt greener production methods.
Naveen Kulkarni, Chief Executive Officer, Quantumzyme Corp., can be reached at +1 (858) 203-0312 or info@quantumzymecorp.com.
Source: Quantumzyme Corp.
